SCHEDULE 13D/A: Indaba Capital Secures Majority Control of Accelerate Diagnostics' Convertible Notes

Indaba Capital Management, L.P. has increased its stake in Accelerate Diagnostics, Inc.'s convertible notes, gaining majority control and significant influence over key debt-related decisions.

Summary

• Indaba Capital Management, L.P. (the "Fund") acquired approximately $12.4 million in aggregate principal amount of Accelerate Diagnostics, Inc.'s 5.00% Senior Secured Convertible Notes due 2026 ("New Convertible Notes") on February 4, 2025.
• This acquisition results in the Fund now owning a majority of the outstanding New Convertible Notes.
• As a result of this majority ownership, the Fund gains the ability to control decisions requiring approval from holders of a majority of the New Convertible Notes under the Indenture and Security Agreement.
• These controlled decisions include, but are not limited to, waivers of certain defaults, consent to supplemental indentures or amendments, direction of remedies for the Trustee, and the removal or nomination of the Trustee or Collateral Agent.
• The Reporting Persons beneficially own 2,751,762 shares of Accelerate Diagnostics' common stock, which are issuable upon conversion of the New Convertible Notes.
• This beneficial ownership represents 9.9% of the Issuer's outstanding common stock, a percentage capped by a beneficial ownership limitation that prohibits conversion in excess of this threshold.
• Without this beneficial ownership limitation, the Reporting Persons would be entitled to receive an additional 2,394,385 shares of common stock upon conversion.
• The percentage of the class represented is based on 25,043,822 shares of Accelerate Diagnostics' common stock outstanding as of November 5, 2024, as reported in the Issuer's Form 10-Q.
• The number of shares issuable upon conversion reflects the Issuer's 1-for-10 reverse stock split, which was effective July 11, 2023, and increases in the principal amount of New Convertible Notes due to interest paid in kind.

Sentiment

Score: 7

Explanation: The sentiment is positive for Indaba Capital as they have successfully increased their control over Accelerate Diagnostics' debt, granting them significant influence. For Accelerate Diagnostics, it represents a shift in control over debt decisions to a single entity, which could be seen as neutral to slightly negative depending on the relationship with Indaba. Overall, the document is a factual report of a strategic investment move.

Positives

• Indaba Capital Management, L.P. has secured majority control over Accelerate Diagnostics' 5.00% Senior Secured Convertible Notes due 2026, giving them significant influence over debt-related decisions.
• The ability to control decisions such as waiving defaults and consenting to amendments provides Indaba Capital with enhanced strategic flexibility regarding the notes.

Negatives

• The increased control by Indaba Capital over the convertible notes could potentially limit Accelerate Diagnostics' flexibility in managing its debt obligations without Indaba's consent.
• Other holders of the New Convertible Notes will have less influence over decisions related to the notes, as Indaba Capital now holds a majority.

Risks

• The document indicates that Accelerate Diagnostics' ability to manage certain aspects of its 5.00% Senior Secured Convertible Notes, such as waiving defaults or amending terms, will now be subject to the approval of Indaba Capital Management, L.P. due to their majority ownership of the notes.

Future Outlook

The document primarily details a change in beneficial ownership and control over specific debt instruments, rather than providing a future outlook for the company's operations or financial performance. It indicates that the principal amount of New Convertible Notes will continue to increase due to interest paid in kind.

Industry Context

This filing reflects an activist investor (Indaba Capital) increasing its influence over a company's debt structure. This is a common strategy in financial markets where investors seek to gain leverage or control, particularly in companies that may be undergoing financial restructuring or strategic shifts. It does not provide broader industry trends for the diagnostics sector, but rather details a specific investment strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased control by Indaba Capital over the company's debt could indirectly affect shareholders by influencing future debt restructuring, financing decisions, or potential defaults. The 9.9% beneficial ownership limit on conversion means immediate dilution from this specific holding is capped.
• Other Noteholders: Other holders of the New Convertible Notes will have significantly reduced influence over decisions related to the notes, as Indaba Capital now holds a majority and can control approvals.
• Company Management: Management's flexibility in managing the company's debt and related agreements will be constrained by Indaba Capital's majority control over the convertible notes.

Next Steps

• Indaba Capital Management, L.P. will continue to exercise control over decisions requiring majority approval of the New Convertible Notes holders.
• The principal amount of New Convertible Notes will continue to increase due to interest paid in kind.

Key Dates

Recommendation

Keywords

Accelerate Diagnostics, Indaba Capital Management, Schedule 13D, Convertible Notes, Debt Control, Beneficial Ownership, SEC Filing, Corporate Governance, Investment Fund, AXDX